REFERENCES
1. Porcari A, Bussani R, Merlo M, et al. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination. Front Cardiovasc Med 2021;8:749523.
2. Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 2020;300:191-5.
3. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2018;2:1046-53.
4. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10.
5. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
6. Lavatelli F, Imperlini E, Orrù S, et al. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB J 2015;29:4614-28.
7. Palladini G, Jaccard A, Milani P, et al. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Clin Chem Lab Med 2017;55:1734-43.
8. Mishra S, Guan J, Plovie E, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol 2013;305:H95-103.
9. Diomede L, Rognoni P, Lavatelli F, et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 2014;123:3543-52.
10. Levinson RT, Olatoye OO, Randles EG, Howell KG, DiCostanzo AC, Ramirez-Alvarado M. Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes. Sci Rep 2013;3:1278.
11. Monis GF, Schultz C, Ren R, et al. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. Am J Pathol 2006;169:1939-52.
12. Brambilla F, Lavatelli F, Di Silvestre D, et al. Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res 2013;12:5642-55.
13. Chang IC, Dispenzieri A, Scott CG, et al. Utility of the serum free light chain assay in the diagnosis of light chain amyloidosis in patients with heart failure. Mayo Clin Proc 2019;94:447-54.
14. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27:941-6.
15. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785-9.
16. Cotten SW, Shajani-Yi Z, Cervinski MA, Voorhees T, Tuchman SA, Korpi-Steiner N. Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study. Clin Biochem 2018;58:100-7.
17. Vercammen M, Meirlaen P, Broodtaerts L, Vande Broek I, Bossuyt X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta 2011;412:1798-804.
18. Schieferdecker A, Hörber S, Ums M, et al. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma. Blood Cancer J 2020;10:2.
19. Schieferdecker A, Hörber S, Ums M, et al. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma. Blood Cancer J 2020;10:2.
20. Muluhngwi P, Sharp CN, Pozzi N, Elin RJ, Jortani SA. Verification of newly FDA-approved kappa and lambda free light chain assays on a previously untested platform. J Appl Lab Med 2019;4:323-30.
21. Campbell JP, Heaney JL, Shemar M, et al. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. Clin Chem Lab Med 2017;55:424-34.
22. Jacobs JFM, de Kat Angelino CM, Brouwers HMLM, Croockewit SA, Joosten I, van der Molen RG. Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. Clin Chem Lab Med 2018;56:312-22.
23. Caillon H, Avet-Loiseau H, Attal M, Moreau P, Decaux O, Dejoie T. Comparison of sebia free light chain assay with freelite assay for the clinical management of diagnosis, response, and relapse assessment in multiple myeloma. Clin Lymphoma Myeloma Leuk 2019;19:e228-37.
24. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
25. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-95.
26. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9.
27. Caponi L, Koni E, Romiti N, Paolicchi A, Franzini M. Different immunoreactivity of monomers and dimers makes automated free light chains assays not equivalent. Clin Chem Lab Med 2018;57:221-9.
28. Caponi L, Koni E, Romiti N, Paolicchi A, Franzini M. Free light chain UV quantification compared with immunochemical measurement: how dimers and monomers may influence the results. Clin Chim Acta 2020;510:278-84.
29. Caponi L, Franzini M, Koni E, Masotti S, Petrini M, Paolicchi A. Discrepancy between FLC assays: only a problem of quantification? Clin Chem Lab Med 2016;54:1111-3.
30. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009;55:1517-22.
31. Dimopoulos M, Kyle R, Fermand JP, et al. International Myeloma Workshop Consensus Panel 3. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701-5.
32. Barnidge DR, Tschumper RC, Theis JD, et al. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS. J Proteome Res 2014;13:1905-10.
33. Bergen HR 3rd, Dasari S, Dispenzieri A, et al. Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin Chem 2016;62:243-51.
34. Barnidge DR, Dasari S, Botz CM, et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res 2014;13:1419-27.
35. Barnidge DR, Krick TP, Griffin TJ, Murray DL. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine. Rapid Commun Mass Spectrom 2015;29:2057-60.
36. Murray DL. Bringing mass spectrometry into the care of patients with multiple myeloma. Int J Hematol 2022;115:790-8.
37. Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J 2021;11:24.
38. Pucci A, Aimo A, Musetti V, et al. Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis. J Am Heart Assoc 2021;10:e020358.
39. Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012;119:1844-7.
40. Winter M, Tholey A, Kristen A, Röcken C. MALDI mass spectrometry imaging: a novel tool for the identification and classification of amyloidosis. Proteomics 2017;17:1700236.
42. Emdin M, Vergaro G, Passino C. Amiloidosi cardiaca come si diagnostica, come si cura.
